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Abstract In a randomized, placebo-controlled trial in
Ghana, 67 onchocerciasis patients received 200 mg/day
doxycycline for 4 or 6 weeks, followed by ivermectin
(IVM) after 6 months. After 6, 20 and 27 months,
eYcacy was evaluated by onchocercoma histology, PCR
and microWlariae determination. Administration of doxy-
cycline resulted in endobacteria depletion and female
worm sterilization. The 6-week treatment was macroWla-
ricidal, with >60% of the female worms found dead,
despite the presence of new, Wolbachia-containing
worms acquired after the administration of doxycycline.
Doxycycline may be developed as second-line drug for
onchocerciasis, to be administered in areas without trans-
mission, in foci with IVM resistance and in areas with
Loa co-infections.
Keywords Doxycycline · Ghana · ivermectin · 
macroWlaricidal · Onchocerca volvulus · Wolbachia
Accession numbers O. volvulus ftsZ: AJ276501 · 
O. volvulus Actin: M84916
Abbreviations
APR O. volvulus aspartic protease
GMI Geometric mean index
IVM Ivermectin
Mf MicroWlaria(e)
DiWsp DiroWlaria immitis Wolbachia surface protein
Introduction
Onchocerciasis (river blindness) is endemic in many sub-
Saharan countries in Africa, with minor foci in Latin Amer-
ica and Yemen [1]. The infection is transmitted through
the bites of blackXies (Simulium spp.) carrying infective
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third-stage larvae, which have developed in the vector from
microWlariae (mf) acquired from other humans during a
preceding blood meal. The female adult worms measure up
to 60 cm in length and have an average life expectancy of
10 years [2], producing millions of mf. The mf migrate to
the skin, causing dermatitis and atrophy, or to the eye,
where they cause inXammation leading to reduced vision
and blindness. Apart from blindness, dermatitis has been
identiWed as a separate factor that signiWcantly reduces the
lifespan of infected people [3]. For many years, onchocerci-
asis was thought to have aVected 17 million people [1].
Since more attention has recently been paid to remote areas
in Central African countries, the estimated number of infec-
tions has risen to more than 37 million [4].
There has been a longstanding eVort to reduce the bur-
den imposed by onchocerciasis using vector control and
mass treatment. EVorts were made to improve the dosage
scheme of ivermectin (IVM), either to include albendazole,
or to develop new drugs such as amocarzine. Current elimi-
nation programmes are based on mass administration of the
antiWlarial drug IVM. The African Programme for Oncho-
cerciasis Control (APOC) relies on a strategy of annual
mass treatment [5]. However, IVM is mainly a microWlari-
cidal and temporarily sterilising drug [6], which has to be
given for many years until all adult worms are sterile or
dead. Some studies indicate that after several rounds of
IVM treatment, female worms are no longer inseminated
[7]. But insemination and fertility of worms did resume
after interruption of IVM administration before all worms
had died [8]. MacroWlaricidal activity of IVM has been
reported after frequent doses [9, 10]. The recent Conference
on the Eradicability of Onchocerciasis [11] concluded that
eradication would not be feasible at coverage rates of 65%
for 35 or more number of years. In addition, there is con-
cern that in some geographic areas worm populations exist
that may exhibit some degree of resistance to IVM [12–14].
Equally important are the costs to individuals, who, in
the absence of a long-acting drug, are faced with the pros-
pect of remaining infected for a decade or more with the
necessity of repeated IVM treatments to prevent ocular or
dermal damage due to the mf. Therefore, it has been a long-
standing aim to identify a non-toxic macroWlaricidal princi-
ple against onchocerciasis. Recently, Wolbachia endosym-
biotic bacteria have been exploited as targets for antiWlarial
drugs with high eYcacy [15]. An earlier, open study
showed that a 6-week administration of 100-mg/day doxy-
cycline to onchocerciasis patients led to a depletion of Wol-
bachia from adult worms [16–18]. This was associated
with a long-term cessation of embryogenesis that was still
observed 18 months after doxycycline treatment. In lym-
phatic Wlariasis due to Wuchereria bancrofti, administration
of 200-mg/day doxycycline for 6–8 weeks led to more than
80% of macroWlaricidal activity [19, 20].
We therefore undertook a placebo-controlled, rando-
mized study with 200 mg/day of doxycycline, administered
for 4-6 weeks, to onchocerciasis patients. The results con-
Wrmed a depletion of Wolbachia as well as interruption of
embryogenesis that led to a cessation of production of new
mf at 20 and 27 months after the onset of doxycycline treat-
ment. We also observed a macroWlaricidal activity of more
than 60% in the 6-week treatment arm at these points of
time.
Methods
Participants
Study site
In the Central Region of Ghana, the area south of the OYn
and west of the Pra rivers is endemic to onchocerciasis but
not for other human Wlarial infections. Both rivers are breed-
ing sites of the vector blackXies Simulium sanctipauli that
have Xight ranges of up to 12 km [21]. The study partici-
pants were recruited in three neighbouring villages in Assin
district situated where the OYn Xows into the Pra. The dis-
tance between the villages and OYn is less than 1.5 km. In
1999, the focus was found to be hyperendemic during a
rapid assessment of 30 men aged more than 19 years in each
village: 75, 86 and 93% nodule carriers and 80, 89 and 90%
mf carriers were found (R. Horstmann, Bernhard Nocht
Institute, personal communication). Mass treatment with
IVM started in 1999 in the district. This focus lies south of
the area of the Onchocerciasis Control Programme in West
Africa (OCP) and transmission is ongoing. Due to the
remoteness of the villages the coverage of IVM mass treat-
ment was rather low until the end of this study [21]. A
reduction in the infection rates of the Xies was not observed
by Garms and colleagues in 2002 (for a detailed map and
vector epidemiology see [21]). During another assessment of
the transmission in 2006 the Simulium infectivity parameters
closely resembled those from other hyperendemic areas
without intervention. The entomologists concluded that a
person might easily receive one or several infective bites per
week (R. Garms, Bernhard Nocht Institute, unpublished
report). The nodule loads found during recruitment for this
study in September 2003 also indicated a high endemicity.
Ethical aspects and study design
The design of this randomized, placebo-controlled, double-
blind study was approved by the Committee on Human
Research and Ethics of the School of Medical Sciences of
the Kumasi University of Science and Technology
(KNUST), Kumasi, Ghana, as well as by the ResearchMed Microbiol Immunol (2008) 197:295–311 297
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Ethics Committee of the Liverpool School of Tropical Medi-
cine . The latter acted as a control body for several studies
on anti-Wolbachia treatment in onchocerciasis and lym-
phatic Wlariasis, which were carried out by a network of
groups funded by the European Union (ICA4-2002-10051).
The study conformed to the principles of the Helsinki Dec-
laration of 1964 (last amended 2002). A Trial Steering
Committee (TSC) as well as a Data Monitoring and Ethics
Committee (DMEC) were established. The trial is regis-
tered at Current Controlled Trials and has the registration
number ISRCTN 71141922.
Informed consent
During a meeting with the village elders and interested vil-
lagers the study was explained in English and then in the
local language Twi. The participants were requested to ask
questions and these were answered. During a survey per-
sons identiWed as eligible to the study were informed indi-
vidually Wrst in English by the study physician and then in
Twi by an experienced teacher and biologist, who was a
team member since 1999. Informed, signed/thumbprinted,
or witnessed consent was obtained from all participants.
Before nodulectomies, the surgeon again explained the pro-
cedure in Twi, in the ward, and answered questions.
Recruitment and examination of patients
Individuals eligible for participation were: nodule carriers of
both sexes, aged 18–62 years, with a body weight of more
than 40 kg, in good health, and without any clinical condi-
tion requiring chronic medication. Physical examinations by
SM and MB included inspection and palpation of onchocer-
comas. Onchocercal skin disease was recorded as papular
and licheniWed dermatitis and depigmentation (“leopard
skin”) [1]. The mf density was assessed by two skin snips as
described in [18]. Before doxycycline resp. placebo treat-
ment and again 3 weeks after treatment onset, hepatic and
renal functions as well as pregnancy were assessed by dip-
stick chemistry using venous blood. Exclusion criteria were:
palpation of less than two onchocercomas, abnormal hepatic
and renal enzymes (AST [0–40 IU/l], ALT [0–45 IU/l], and
creatinine [3–126 mol/l]), pregnancy, breast-feeding, intol-
erance to doxycycline, and alcohol or drug abuse.
Interventions
Patients were treated in September2003 and October 2003
(Fig. 1). There were three treatment arms: (1) 6 weeks
200 mg/day doxycycline; (2) 4 weeks 200 mg/day doxycy-
cline, followed by 2 weeks matching placebo; (3) 6 weeks
matching placebo. Participants received two 100 mg cap-
sules of Vibramycin® or matching placebo supplied by
PWzer. The treatment was monitored by a trial physician
(MB) as daily-observed treatment (DOT). This included
daily monitoring in the villages of adverse side eVects on a
hardcopy standardized patient form.
After 6 months, a limited number of nodules were
excised from some patients of the 6-week doxycycline and
the placebo groups harbouring many onchocercomas, to
conWrm the depletion of Wolbachia. One nodulectomy on
patients with several sites with onchocercomas does not
decrease the mf densities (Büttner, unpublished data). Six
months after the beginning of the study and after this Wrst
round of nodulectomy, the patients received 0.15 mg/kg
IVM to more quickly deplete skin mf.
Based on the results of previous studies ([18], and
unpublished data), patients were nodulectomised 20 and/or
27 months after the start of the study in May2005 and
November 2005. In addition, three patients who had been
absent before, and one patient who had not been completely
nodulectomised, were operated after 39 months in Novem-
ber 2006. For the nodulectomies patients were admitted at
the district hospital in Dunkwa for two or more days. The
nodules were excised aseptically under local anaesthesia in
a separate room by an experienced surgeon (PK) as previ-
ously described [18,  22]. Treatment of the wounds was
started in the hospital and continued in the villages by the
trial physician. During drug and wound treatment the
patients and a few other villagers were also treated for other
medical conditions such as respiratory and intestinal infec-
tions, fungal infections of the skin, fever assumed to be
caused by malaria, fresh wounds and old ulcers. Addition-
ally, four study patients underwent hernia operations.
The study patients had been asked not to participate in
IVM mass treatment between September 2003 and Novem-
ber 2005. They were treated by us with IVM in November
2005–2006, when a Wnal examination for nodules was
made after 39 months in November 2006.
Objectives
The study had two objectives: (1) To study in a placebo-
controlled manner the eYcacy of 4 and 6-week treatment
with doxycycline followed by IVM, in order to deWne the
minimum regimen needed to achieve Wolbachia depletion
and complete sterilization of adult female worms, leading
to a reduction of skin mf over a long period. Two and
3 weeks of doxycycline were not suYcient in the previous
studies (unpublished data). (2) To assess a potential macro-
Wlaricidal activity of doxycycline on Onchocerca volvulus.
Outcomes
The primary outcome was the assessment of sustained
eVects of doxycycline treatment on worm fertility and298 Med Microbiol Immunol (2008) 197:295–311
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worm survival. Worm fertility was measured (1) by obser-
vation of the presence or absence of normal or degenerated
embryos in female worms and of mf in the human nodule
tissue using histology, and (2) by analysis of the presence
and quantity of skin mf. Worm survival was measured
as the proportion of living and dead worms detected by
histology.
Sample size
The sample size was calculated for the presence of mf in
the patients’ skin. Applying Fisher’s exact test, the power
calculation resulted in a sample size of 20 patients per treat-
ment arm for a power of 90% at a signiWcance level of
0.001, in order to observe a signiWcantly higher proportion
of doxycycline-treated patients without skin mf compared
to placebo. Allowing a dropout rate of 20% the calculation
suggested starting treatment with 25 patients for each arm.
This sample size was also suggested on the basis of histo-
logical analysis of female worms in extirpated onchocerco-
mas: Twenty patients with two or more nodules containing
two or more female worms would result in the examination
of about 100 female worms, a number found to be suYcient
in earlier studies [16–18, 23–25].
Fig. 1 Flow chart of patients 
who took part in the study. a Pa-
tients who had received iver-
mectin (IVM) at the 6 months 
point of time. b Only patients 
who had received ivermectin at 
6 months were analysed. The to-
tal numbers comprise the pa-
tients who underwent 
nodulectomy and had received 
ivermectin (see footnote a) plus 
patients who were only available 
for skin snipping (but not for 
nodulectomy) at the respective 
point of time. c Four additional 
patients (two from each of the 
doxycycline groups), three of 
whom were not available for 
nodulectomy between 6 and 
27 months, were nodulecto-
mised at 39 months, increasing 
the total number of nodulecto-
mised patients to 14/22 and 19/
22 in the 4 and 6-week groups, 
respectively
Excluded (n=5)
Not meeting inclusion 
criteria by
clinical chemistry (n=5)
Randomized  (n = 76)
Allocated to doxycycline 6 weeks  (n=25)
Received allocated intervention  (n=22)
Did not receive intervention  (n=3)
Reason: absent
Examined for skin mf (n=25) 
Allocated to placebo  (n=25)
Received allocated intervention (n= 23)
Did not receive intervention  (n=2)
Reason: absent
Examined for skin mf  (n=25) 
Received IVM at 6 months  (n=15)
Did not receive IVM  (n=7)
Reason: absent
Received IVM at 6 months  (n=18)
Did not receive IVM  (n=5)
Reason: absent
Analysis at 20 months:
Nodulectomised (n=13)
Of these, patients with IVM 
a
(n=10)
Not nodulectomised (n=9)
Reason: absent
Examined for skin mf (n=14) 
b
Of these,10 operated, 4 not operated
Analysis at 20 months:
Nodulectomised (n=16)
Of these, patients with IVM 
a
(n=12)
Not nodulectomised (n=7) 
Reason: absent
Examined for skin mf (n=18) 
b
Of these, 12 operated, 6 not operated
Analysis at 27 months:
Nodulectomised (n=5)
Of these, patients with IVM a (n=3)
Not nodulectomised (n=17)
Reasons: absent  (n=8),
nodulectomy completed
at 20 months  (n=9)
Examined for skin mf (n=10) b
Of these, 3 operated, 7 not operated
Analysis at 27 months:
Nodulectomised (n=7)
Of these, patients with IVM a (n=5)
Not nodulectomised (n=16)
Reasons:  absent  (n=4),
nodulectomy completed  
at 20 months  (n=12)
Examined for skin mf (n=15) b
Of these, 5 operated, 10 not operated 
Allocated to doxycycline 4 weeks  (n= 26)
Received allocated intervention  (n = 22)
Did not receive intervention  (n=4)
Reasons: absent (n=3), 
bloody  diarrhoea  (n=1)
Examined for skin mf (n=26) 
Received IVM at 6 months  (n=11)
Did not receive IVM  (n=11)
Reason: absent
Analysis at 20 months:
Nodulectomised (n=7) 
Of these, patients with IVM 
a
(n=6)
Not nodulectomised (n=15)
Reasons: absent (n=14), dead (n=1)
Examined for skin mf (n=10) 
b
Of these, 6 operated, 4 not operated
Analysis at 27 months:
Nodulectomised (n=7)
Of these, patients with IVM a (n=5)
Not nodulectomised (n=15)
Reasons:  absent  (n=10),
nodulectomy completed 
at 20 months  (n=5)
Examined for skin mf (n=10) b
Of these, 5 operated, 5 not operated
Analysis at 6 months:
Nodulectomised (n=11)
Not nodulectomised (n=11)
Reason: not selected for operation
Examined for skin mf (n=16)
Analysis at 6 months:
Nodulectomised (n=16)
Not nodulectomised (n=7)
Reason: not selected for operation 
Examined for skin mf (n=16)
Analysis at 6 months:
Nodulectomised (n=0)
Not nodulectomised (n=22) 
Reason: not selected for operation 
Examined for skin mf (n=0)
Selected and enrolled 
according to clinical 
inclusion criteria:
palpable nodules, no 
visible pregnancy or 
breast-feeding (n= 81)
Summary:
Nodulectomised (n=22/23)
Not operated 6-27 months  (n=1) 
Reason: moved  (n=1)
Summary c:
Nodulectomised (n=12/22)
Not operated 6-27 months ( n=10)
Reasons: dead  (n=1), moved
(n=6), refused (n=3)
Summary c:
Nodulectomised (n=18/22)
Not operated 6-27 months (n=4)
Reasons: moved  (n=2), 
refused  (n=2)Med Microbiol Immunol (2008) 197:295–311 299
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Randomisation
The random allocation sequence was computer-generated
by AH (StatView® version 4.5. for Macintosh). Simple ran-
domisation without restrictions was used. The random allo-
cation sequence was implemented by packing tablet
containers according to the consecutive running numbers to
which the mode of treatment had been allocated and which
had been assigned to the patients.
Blinding
Blinding was assured by the exclusion of persons involved
in randomisation or tablet packaging in any clinical or labo-
ratory assessments as described [20]. At the beginning of
the study and during drug treatment all members of the
team and the patients were blinded. Patients were blinded
to group allocation. A few nodules were excised from
patients with many onchocercomas at 6 months after the
beginning of the study to conWrm the depletion of Wolba-
chia. These patients had been selected by AH without giv-
ing information on treatment to other members of the team
(only a list with patient identiWcation numbers was pro-
vided). All persons involved with the assessment of nod-
ules and skin biopsies in the laboratory were kept blinded
until the end of the analysis.
Laboratory methods
Nodule preservation
For histological analysis, we used either complete small nod-
ules or more than half of medium or large nodules to allow
assessment of worm numbers and status. DeWnitions of
“medium” and “large” were diameters of 5–10 mm and more
than 10 mm, respectively. For histology the nodules or por-
tions of them were Wxed in 80% ethanol or 4% phosphate-
buVered formaldehyde solution. For PCR analysis the minor
portions or total small nodules were placed immediately into
ice-cold RNAlater solution (Ambion, Cambridgeshire, UK),
kept at 4°C overnight and then frozen until further process-
ing. The presence of worms was veriWed by worm actin PCR.
If possible, cuts were made such that the piece that was cut
away for PCR constituted the minor portion of worm-con-
taining tissue (“worm nest”) of which the larger one corre-
sponded to the piece used for histology. Since this could not
always be guaranteed macroscopically we analysed the
pieces of the nodules for PCR and histology independently.
Histology
Samples were embedded in paraYn and several sections
were stained by hematoxylin and eosin. For selected sec-
tions, Giemsa stains and Gomori’s method for iron were
used. For immunostaining, the alkaline phosphatase anti-
alkaline phosphatase technique (APAAP) was applied
according to the manufacturer’s instructions (DakoCytoma-
tion, Hamburg, Germany). To demonstrate the presence of
Wolbachia, a rabbit anti-serum against DiroWlaria immitis
Wolbachia surface protein (DiWsp) was used at a dilution
of 1:1,000 [26]. Worm vitality was assessed with rabbit
anti-serum against a cathepsin D-like lysosomal aspartic
protease of O. volvulus (APR) at a dilution of 1:1,000 [27].
As secondary antibody, an anti-rabbit mouse monoclonal
antibody was used (clone MR12/53, DakoCytomation).
Fast Red TR salt (Sigma, Deisenhofen, Germany) was
applied as the chromogen, and hematoxylin functioned as a
counter stain (Merck, Darmstadt, Germany).
Assessment criteria were as previously described [18,
23]. Criteria for dead Wlariae were worm portions calciWed
without cuticle or nearly completely absorbed. Further
characteristics for death of a worm included loss of body
wall integrity, loss of nuclei [23], and absence of APR-
staining [27] (Fig. 2). Very degenerated worms, still APR-
positive, were classiWed as moribund according to Duke
et al. [28, 29] and grouped in the category “dead”. But this
criterion was used rarely, mainly for worms with neo-
plasms. “Living” means alive at the time of nodulectomy.
All developmental stages from the stage of two cells to the
stretched mf in the uterus were classiWed as “embryos” [18,
23]. When only the stretched mf were degenerated and the
other embryos were not, embryogenesis was recorded as
“normal” for the purpose of this doxycycline-oriented
study. It was assumed that degenerated stretched mf were
due to IVM treatment [30, 31]. The sections were assessed
by two authors (DWB and SS) independently. When the
examiners did not agree on the Wndings, the slides were
re-examined, which always led to a consensus. Examination
and re-examination were performed without information on
the treatment.
PCR
For the analysis of the extent of Wolbachia depletion by
quantitative PCR, only nodules positive for worm actin
were included in the analysis. DNA was extracted using
Trizol reagent following the manufacturer’s protocol (Invit-
rogen, Karlsruhe, Germany) by homogenising 4 £ 30 s at
6,800 rpm in a Precellys 24 (PeqLab, Erlangen, Germany)
using 2.8-mm steel beads. DNA was dissolved in 0.8 mM
NaOH, pH adjusted to 7.4 with 1 M HEPES (Invitrogen),
and further puriWed using the QIAamp Mini Kit (Qiagen,
Hilden, Germany) following the protocol for crude cell
lysates.
The Wolbachia ftsZ gene was quantiWed from the puri-
Wed DNA by real-time PCR (qPCR) using the following300 Med Microbiol Immunol (2008) 197:295–311
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conditions: 1£ HotStar Taq Polymerase buVer (Qiagen),
200 M dNTP, 200 nM each of forward (5-AGGAAT
GGGTGGTGGTACTG-3) and reverse (5-CTTTAACC
GCAGCTCTTGCT-3) primers, 0.2 l of Sybr Green
(1:1,000 diluted in DMSO, Roche, Mannheim, Germany),
2.5 U HotStar Taq, and 2 l DNA in a 20 l reaction. The
gene was ampliWed in a Rotorgene 3000 (Corbett Research,
Sydney, Australia) using the following conditions:
1 £ 15 min at 95°C, 40 cycles of 94°C for 15 s, 55°C for
30 s, 72°C for 20 s. Fluorescence was acquired on the FAM
channel. Nematode actin was measured as described [32].
Copy numbers for each gene were calculated using a modi-
Wcation [20] of the comparative quantiWcation formula as
described in [33].
MicroWlariae
MicroWlariae were assessed at recruitment and at 6, 20 and
27 months after the onset of doxycycline/placebo treat-
ment. For mf analysis, two skin biopsies of 1–3 mg were
taken from the buttocks using a Holth punch. Each biopsy
was immersed in 100 l of 0.9% NaCl solution in a well of
a microtiter plate (Nunc, Roskilde, Denmark). The skin
biopsies were incubated at room temperature for 6–20 h.
The solution was then transferred onto a slide for micro-
scopic examination. The biopsies were weighed using a
Sartorius electronic balance (Göttingen, Germany). Micro-
Wlarial data are given as median with range, and as geomet-
ric mean. For the latter, the calculation according to
Fig. 2 DiVerentiation between living and dead O. volvulus worms by
immunohistology. “Living” is deWned as alive before Wxation of nod-
ules. a At left, a living male worm labelled red (arrowhead) and at
right, a dead female with strongly degenerated organs after doxycy-
cline and ivermectin. b Detail of the same slide as (a) but from another
region showing the red labelling of the epithelium of the testis by anti-
serum against APR (open arrowhead) and of the median chord (closed
arrowhead) of the living male in contrast to the dead female (arrow).
The testis is Wlled with sperms. c A living male with well-labelled epi-
thelium of the testis (open arrowhead) and hypodermis (closed arrow-
head) and an unlabelled dead female (black arrow) from a placebo
patient not treated with ivermectin. d A moribund female with a pleo-
morphic neoplasm in the pseudocoeloma cavity (black arrow) from a
placebo patient 14 months after ivermectin. The intense blue staining
of the gut indicates the older age of these worms and it hides the red
labelling of APR on the photos. All patients were operated 27 months
after the onset of the study. Sections were stained with antiserum
against a lysosomal aspartic protease (APR) of O. volvulus only label-
ling the organs of “living” but not of dead Wlariae. Scale bar =1 0 0mMed Microbiol Immunol (2008) 197:295–311 301
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Williams was performed as used by WHO for standardiza-
tion of mf results [34]. Since the geometric mean cannot
use zero, the calculation uses mf +1 values, and from the
calculated mean, 1 is subtracted afterwards [34].
Deviations from the study protocol
The methods described above were those actually used.
New information based on the results of the studies that we
had performed in 2000–2003 led to some deviations from
the original study protocol. The time for nodulectomy was
postponed from 4, 18 and 24 months to 6, 20 and 27 months
for a better assessment of worm fertility and survival.
Patients of the 4 weeks group were not nodulectomised at
6 months in order to save their nodules for later follow-up
times since data analysis from other studies [35] suggested
that 4 weeks of doxycycline might be the optimal regimen,
and it was clear that the anti-parasitic eVect of doxycycline
would be best observed at later points of time. We also
decided to include patients who had taken one or two doses
of IVM and those with less than 10 mf/mg, since we knew
that we could diVerentiate between the eVects of doxycy-
cline and of IVM taken before recruitment, as long as IVM
had not been taken more than one to two times. We also
accepted patients older than 50 years with many nodules.
Since IVM was planned to be given after the Wrst round
of nodulectomies, it had to be administered at 6 months
instead of 4 months. Since skin snipping without the pros-
pect of nodulectomy would have led to reduced compliance
at later follow-up times, we omitted mf analysis at
6 months in the 4-week doxycycline group. Sonography
was used to detect onchocercomas and these results will be
published elsewhere.
A third objective mentioned in the protocol was the
analysis of whether treatment with IVM several months
after the end of the doxycycline treatment led to a reduction
of adverse reactions to IVM. Severe side eVects as described
by Awadzi [36] and as we had seen in Uganda [37], were
not observed. Since no diVerence between placebo and
doxycycline was seen, we do not report this topic here.
Statistical methods
The presence of mf in the skin of the patients, was com-
pared between the three treatment groups by Fisher’s exact
test, comparing all treatment groups Wrst, followed by all
possible pair-wise comparisons in case of a signiWcant
result for the Wrst test.
In addition, regression analyses were performed using
alternating logistic regression [38, 39], as implemented in the
SAS-Procedure Genmod®, to analyse and estimate the rate of
nodules with “normal” embryogenesis, “living” female
worms, or mf in the human tissues of the nodule and com-
pare them between placebo and the two doxycycline treat-
ment arms. This procedure allowed taking into consideration
a potential dependency between the nodules in one patient.
Further analyses were performed on the per nodule level
using the Kruskal–Wallis test, the Mann–Whitney-U test and
the Wilcoxon Signed Rank test for quantitative data. The
Chi-square test was used for qualitative data. These calcula-
tions were done using Stat View® software version 4.5.
Results
Participant Xow and recruitment
Figure 1 illustrates the trial proWle in the way the study was
performed. Deviations of the original protocol are
described in the section, “Methods” In September 2003
during surveys in the three villages, 76 patients who met
the clinical inclusion criteria were recruited from a poten-
tial 81 candidates. Five of the 81 had at least one exclusion
criterion in clinical chemistry when tests were performed
subsequent to clinical examination. The 76 patients were
randomly allocated to the 3 treatment arms, and 67 patients
completed the allocated treatment. Adherence to treatment
was generally high. Two to four individuals in each treat-
ment group failed to complete the course of doxycycline or
placebo. The failure was usually due to absence from the
village. In one case the treatment was stopped after bloody
diarrhoea on day 3. A number of patients who had received
placebo or doxycycline for 6 weeks underwent a nodulec-
tomy on one site of the body 6 months after recruitment.
The excised nodules contained 29 and 32 living females
(Table 2), enough Wlariae to assess the early activity against
the Wolbachia. The main points of time for the assessment
were 20 and 27 months after the beginning. Four of the
patients absent at that time were oVered another chance for
nodulectomy and were nodulectomised 1 year later in
November 2006. Including these, a total of 22 of 23 pla-
cebo patients, 19 of 22 patients treated 6 weeks with doxy-
cycline, and 14 of the 22 patients of the 4-week group were
nodulectomised. Most of those who did not undergo nodu-
lectomy had moved since study onset. The nodules excised
in 2005 permitted an assessment of 149 females and 48
males Wlariae in the 6-week group and 171 females and 53
males in the placebo group, providing more worms than
needed for a judgement of worm vitality.
Baseline data
Table 1 shows the characteristics of the three groups of
patients that completed the allocated treatment.
Before study onset, the numbers of onchocercomas
did not diVer between the three groups. The mf loads of the302 Med Microbiol Immunol (2008) 197:295–311
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6-week doxycycline group were higher than those in the
other two groups.
Outcomes
Depletion of Wolbachia by doxycycline
The presence of Wolbachia endobacteria in worm tissues
was examined by immunohistology using anti-serum
against Wolbachia surface protein (Table 2). Worms were
classiWed as having many, few, or no bacteria as described
previously [18]. Depletion of Wolbachia after doxycycline
was already clearly visible at 6 months after the onset of
treatment with 72% of 32 female and 78% of 18 male
worms being Wolbachia-negative in the 6-week doxycy-
cline group in contrast to 10% of 29 female and 0% of 8
male worms in the placebo group. At 20 months most pla-
cebo-treated living worms contained many bacteria, and
Table 1 Characteristics of pa-
tient groups that completed 
treatment (baseline data)
Characteristics of patient groups Placebo  Doxycycline 
(4 weeks)
Doxycycline 
(6 weeks)
Baseline data
No. of individuals 23 22 22
Sex ratio, male/female 15/8 18/4 18/4
Mean age, years (range) 39
(20–61)
39
(23–58)
41
(19–59)
Mean weight, kg (range)  54
(40–67)
54
(49–65)
56
(40–73)
No. of palpable nodules
Median (range)
5
(2–13)
6
(2–13)
5
(2–13)
No. of mf carriers 20 20 22
No. of mf/mg in the skin
Median (range)
9
(0–98)
6
(0–78)
21
(2–175)
No. with onchodermatitis 1 5 7
No. with depigmentation 2 8 3
No. of individuals who took 
previously ivermectina
Months before recruitment
Mean (range)
16
18
(5–41)
8
15
(1–41)
14
19
(5–40)
No. with complete treatment
Less days of treatment
22
1 £ 28
20
2 £ 41b
19
1 £ 40, 2 £ 41
a Three patients had taken iver-
mectin two times before study 
onset; the rest had taken iver-
mectin a single time
b The 1 day that the two patients 
missed was during the doxycy-
cline part of the treatment
Table 2 EVect of doxycycline treatment on presence of Wolbachia in worms: results of immunohistology
a While the number of all living worms is given to make the numbers consistent to the other tables, in some instances it was not possible to dis-
tinguish if a male worm had many, few or no Wolbachia, due to too little worm material in the respective histological sections. Therefore, “All”
is not always a summary of the three categories for males
b,c SigniWcant diVerence between the respective doxycycline and the placebo group regarding the distribution between many, few and no Wolba-
chia at the respective time points (b P < 0.0001; c P < 0.002, Chi-square test)
d,e SigniWcant diVerence between the two doxycycline groups regarding the distribution between many, few and no Wolbachia at the respective
time points (d P =0 . 0 3 ;   e P = 0.003, Chi-square test)
Treatment group Time 
(months)
Number of 
patients/nodules
Number of living female worms Number of living male worms
All With Wolbachia Alla With Wolbachia
Many Few None Many Few None
Placebo 6 13/14 29 26 0 3 8 7 1 0
20 16/51 70 58 7 5 25 18 2 3
27 7/38 61 50 9 2 25 14 3 5
Doxycycline (4 weeks) 20 7/36 27 3 4 20b 21 3 2 16b
27 7/23 20 4 2 14b 96 2 1
Doxycycline (6 weeks) 6 11/19 32 1 8 23b 18 1 2 14b
20 13/62 42 9 033 33b,d 20 3 2 15b
27 5/27 15 5 0 10b 14 2 0 11c,eMed Microbiol Immunol (2008) 197:295–311 303
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only 7% of 70 female and 12% of 25 male worms stained as
Wolbachia-negative. Since Wolbachia are not evenly dis-
tributed in the Wlarial tissues, this was expected and it had
previously been observed [18]. In contrast to the placebo
group, after 6 weeks of doxycycline treatment, 79% of 42
female and 75% of 20 male worms did not contain bacteria
anymore. After 4 weeks of doxycycline 74% of 27 female
and 76% of 21 male worms were found Wolbachia-nega-
tive. Equivalent diVerences were still seen at 27 months
after treatment (Table 2). At 39 months after doxycycline
13 of 21 female worms in 20 nodules from 4 patients
showed no bacteria. The presence of Wolbachia in the pla-
cebo group was retained after IVM treatment.
The data obtained by histology were corroborated by
real-time PCR, where the Wolbachia load can be ana-
lysed quantitatively (Table 3). Since there is variation
between nodules with regard to the amount of human tis-
sue in relation to worms we normalized the Wolbachia
loads to Onchocerca actin, as described [32]. Nodules
without an actin signal were not considered for further
analysis. Depletion of Wolbachia after doxycycline,
demonstrated by quantitative PCR, was observed at all
follow-up points of time. At 6, 20 and 27 months nodules
from both doxycycline groups showed Wolbachia levels
that were almost tenfold lower than the nodules from the
placebo-treated group (Table 3). This was sustained over
the observation period, with no statistical indication of an
increase.
Interruption of embryogenesis by doxycycline
For this analysis one has to consider the diVerent eVects on
embryogenesis by doxycycline and by one or two doses of
IVM, as described in the “Methods” (histology). Since the
focus of this study is the doxycycline-induced eVects, the
term “degeneration” (Table 4) refers to early embryogene-
sis and is aVected only by doxycycline; while degeneration
only of the stretched Wlariae, an eVect of IVM, was counted
as “normal” (Table 4). In the placebo group, we observed
that 27 of 70 female worms (39%) had normally developed
embryos at 20 months, and mf were observed in 24% of the
nodules analysed (Table 4). In contrast, only 3 of 27 (11%)
and 3 of 42 (7%) of the female worms were found with nor-
mal embryogenesis in the 4 and 6 weeks doxycycline treat-
ment arms, respectively. No mf were found in the 98
onchocercomas excised at 20 months from the patients of
the doxycycline arms. Equivalent diVerences were seen at
27 months and were already observed at 6 months in the
6 weeks doxycycline group. At 39 months after doxycy-
cline, 2 of 21 female worms showed embryogenesis and 2
of 20 nodules from four patients contained mf, respectively
(data not shown). These data were in accordance with those
of our previous study [18].
Since the nodules of one patient and the nodules stem-
ming from the same site of the body of a patient could
a priori not be regarded as independent, we used alternating
logistic regression (see “Methods”), as implemented in the
Table 3 EVect of doxycycline treatment on Wolbachia loads in worm tissue: results of quantitative PCR
DNA was prepared from portions of onchocercomas extirpated at the indicated time points, and the copy numbers of the Wolbachia single copy
gene ftsZ and the nematode gene actin were determined by quantitative PCR
a Median
b SigniWcant diVerences in the respective doxycycline compared to the placebo group (Mann–Whitney U test). No signiWcant diVerences between
the two doxycycline groups were observed at any time point
Treatment group Time 
(months)
Number of 
patients/nodules 
Index ftsZ/actina
(10–90th percentiles)
P valueb
Placebo 6 12/31 3.24
(0.3–19.5)
–
20 16/70 3.04
(0.2–27.0)
–
27 7/19 1.85
(0.1–29.1)
–
Doxycycline (4 weeks) 20 7/13 0.47
(0.01–3.2)
0.0016
27 5/15 0.20
(0.04–3.31)
0.0011
Doxycycline (6 weeks) 6 10/33 0.19
(0.02–4.4)
0.0005
20 12/22 0.30
(0.04–6.9)
<0.0001
27 5/11 0.13
(0.04–1.4)
0.0004304 Med Microbiol Immunol (2008) 197:295–311
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SAS-Procedure Genmod® [39], to analyse the rate of nor-
mal embryogenesis and the presence of nodular mf, and
mathematically taking into account the potential interde-
pendency of worms in nodules and nodules in patients. This
analysis conWrmed that both the rate of normal embryogen-
esis per nodule and the rate of the modelled likelihood for
the presence of mf in the nodule tissues, based on the data
given in Table 4, are much lower in nodules from 4 to
6 weeks doxycycline than from placebo patients at month
20. The estimated rate of nodules with normal embryos was
8.3% [CI 4.3–15.3%] for 4 weeks doxycycline, 4.9% [CI
2.2–10.4%] for 6 weeks doxycycline, and 44.2% for pla-
cebo, showing clear diVerences between both treatment
groups and placebo (P < 0·0001 for both comparisons) but
no evidence for a diVerence between 4 and 6 weeks doxy-
cycline (P = 0.3). The estimated likelihood for the presence
of nodular mf was 0 [CI 0.0–10.3%] for the 4 weeks doxy-
cycline group and 1.7% [CI 0.4–6.5%] for the 6 weeks
doxycycline group as compared to placebo with 31.5% [CI
20.4–45.3%], P < 0·0001.
Together, these results conWrm our earlier Wndings [17,
18] that one of the eVects of doxycycline on female worms
is a sustained cessation of embryogenesis and mf produc-
tion in all or most of the worms (see “Discussion”).
Sustained reduction of skin mf loads by doxycycline
Table 5 presents the skin mf load before treatment and at
follow-up points of time. All patients who were available
for follow-up underwent skin snipping regardless of their
IVM uptake. However, IVM itself aVects skin mf. There-
fore, for the analysis of skin mf in Table 5 only patients
who had taken IVM at 6 months were included. The data
from patients without IVM were measured but were not
considered, although inclusion of these patients did not
alter the signiWcance of the data (not shown).
At month 20, in the placebo group that had received only
IVM, mf loads were reduced but 17 of 18 patients were still
positive for skin mf. In contrast, in both groups that had
received doxycycline plus IVM, the median mf level was
much more reduced, being zero in the doxycycline 6 weeks
group. In both doxycycline groups, the proportion of
patients, who were still positive for skin mf, was signiW-
cantly lower than in the placebo group (Fisher’s exact test,
Table 5). At month 27, the signiWcant and sustained reduc-
tion of skin mf as compared to placebo was still maintained
in the 6 weeks doxycycline group. There was less reduction
of skin mf in the 4 weeks group, while in the placebo
group, there was a clear resumption of mf production, con-
Wrming earlier reports that show that production of mf starts
a few months after the administration of IVM [24, 40].
MacroWlaricidal activity of doxycycline
After a long observation period of 20 and 27 months, a dis-
tinct macroWlaricidal eVect on female worms was observed
in onchocercomas from the doxycycline-treated groups
(Table 6). Examples of dead compared to living worms in
onchocercoma sections are presented in Fig. 2. At 6 months
after study onset, the proportions of dead female and male
worms in the 6-week doxycycline group were similar to the
placebo group. In the latter, proportions of dead worms
remained stable through all follow-ups and they were in
accordance to other published results [18, 23, 25, 28]. In the
Table 4 EVect of doxycycline treatment on microWlariae production: results of immunohistology
No signiWcant diVerences between the two doxycycline groups were observed at any time point
a Normal embryogenesis only refers to the younger embryonic stages, excluding degenerated stretched mf
b, c, d SigniWcant diVerences between doxycycline and placebo groups regarding the presence of degenerated and normal embryogenesis at the
respective time point. b P =0 . 0 3 ;  c P = 0.0003, d P = 0.001 (Chi-square test)
e, f, g, h SigniWcant diVerences between doxycycline and placebo groups regarding the proportions of nodules with intact mf at the respective time
point. e P = 0.001; f P = 0.03; g P < 0.0001, h P = 0.004 (Fisher’s exact test)
Treatment group Time 
(months)
Number 
of patients 
Number of living female worms Number of nodules
All Embryos All With intact mf
None Degenerated Normala
Placebo 6 13 29 16 5 8 14 6  (43%)
20 16 70 26 17 27 51 12  (24%)
27 7 61 30 10 21 38 10  (26%)
Doxycycline (4 weeks) 20 7 27 13 11 3b 36 0 (0)e
27 7 20 10 8 2b 23 2 (9%)
Doxycycline (6 weeks) 6 11  32 10 21 1c 19 1 (5%)f
20 13 42 24 15 3d 62 0 (0)g
27 5 15 9 5 1 27 0  (0)hMed Microbiol Immunol (2008) 197:295–311 305
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placebo group a few polymorphic neoplasms were
observed (Fig. 2d). These neoplasms represent a killing
mechanism of IVM described by Duke et al. [29]. In con-
trast, in both doxycycline groups a signiWcant and biologi-
cally relevant increase of dead females was seen at 20 and
27 months, compared to placebo. The proportion of dead
females was highest in the 6-week group at 20 and
27 months (>60%). A lower but signiWcant increase in dead
males was seen in both doxycycline treated groups. The
ratio of all living female to living male worms, summarised
for both doxycycline groups and for 20 and 27 months, was
1.6/1 compared to 2.6/1 in the placebo group. The diVer-
ence is signiWcant (P = 0.037, Chi-square test) and shows
the lower lethality of doxycycline on male worms.
Table 6, right set of columns, illustrates the changes in
the number of living female worms per nodule. This calcu-
lation is not compromised by the potential bias that some
dead worms may have been already absorbed. The data
conWrm the results shown by histology. At 6 months no
macroWlaricidal eVect by doxycycline was seen. At 20 and
27 months the numbers of living females per nodule were
signiWcantly lower in both doxycycline groups when com-
pared to the placebo group.
Alternating logistic regression analysis was used to esti-
mate the rates of nodules with living female worms at
20 months. In the 4-week doxycycline group, 52.2% of nod-
ules were calculated to contain a living female [CI 32.1–
71.6%] and in the 6-week doxycycline group, 38.2% of nod-
ules were calculated to contain a living female [CI 22.5–
56.0%], in contrast to 79.2% [CI 58.3–90.3%] in the placebo
group. The proportions of dead and living female worms are
in this analysis are almost identical to the results in Table 6,
where the dead and living worms were analysed without con-
sidering the potential interdependency of worms in nodules.
Ancillary analyses
Palpation of nodules in November 2006
At 39 months after study onset, 46 of the 67 treated and
four new untreated patients were examined for nodules and
the  Wndings compared with the previous survey and the
Table 5 EVect of doxycycline treatment on microWlariae production: mf loads in skin snips
a Geometric mean intensity (GMI), median values, and ranges of mf/mg skin are shown. The GMI was calculated using the log (x + 1) method
according to Williams
b Changes in median levels from baseline (at 0 month) in skin mf levels at 6, 20, and 27 months in doxycycline or placebo groups were assessed
(Wilcoxon signed rank test)
c, d SigniWcantly fewer patients were mf-positive in the respective doxycycline groups compared to the placebo group at 20 months after study
onset. c P =0 · 0 4 1 ;   d P < 0·0001 (Fisher`s exact test). No signiWcant diVerences between the two doxycycline groups were observed at any time
point
Treatment group Time 
(months)
Number of 
patients assessed
Mf levelsa Number of patients 
with skin mf
(% total) GMI Range Median P valueb
Placebo 0 25 8.5 0/98 10.3 – 23
(92%)
6 16 14.3 0/64 27.6 0.379 15
(94%)
20 18 4.4 0/58 4.3 0.011 17
(94%)
27 15 5.5 0/75 3.0 0.394 12
(80%)
Doxycycline (4 weeks) 0 26 6.5 0/78 6.2 – 25
(94%)
20 10 0.7 0/6 0.3 0.012 6c
(60 %)
27 10 1.3 0/23 0.4 0.839 5
(50%)
Doxycycline (6 weeks) 0 25 19.1 0.3/175 13.2 – 25
(100%)
6 16 14.7 0.4/60 25.2 0.049 16
(100%)
20 14 0.1 0/1 0·0 0.001 3d
(15%)
27 10 0.8 0/6 0·6 0.007 7
(70%)306 Med Microbiol Immunol (2008) 197:295–311
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records made at the times of nodulectomy. Three of the 46
treated patients had not yet been nodulectomised at all, and
one patient had not been completely nodulectomised (see
Fig. 1, footnote c). Of the 42 nodulectomised patients, 27
had no palpable nodules. Only two patients had one nodule
each, which had been observed already before the nodulec-
tomies. Thirteen patients had 32 new nodules. One patient
presented 11 new nodules. His profession suggested an
extremely high exposure to Simulium Xies (“I catch crabs in
the river OYn everyday”). We conclude that since all pal-
pable nodules except for two had been excised for analysis,
there had been no selection of nodules. The eight patients,
who had not been nodulectomised, presented 33 nodules
(range 3–6). The mean number of nodules was 4.1 com-
pared to 0.8 in the nodulectomised patients (P < 0.0001).
The eight nodule carriers were nodulectomised after exami-
nation (see results on month 39 in the sections before).
Doxycycline without IVM
A sub-analysis was done based on eight patients from the
doxycycline groups who had never received IVM before or
during the study. Nodulectomy of two 6-week patients
resulted in 12 nodules with 17 living female worms (82%
dead). From the six 4-week patients, 44 nodules were
obtained with 78 female worms (40% dead). Although the
numbers are small and comprise all late points of time (20,
27 and 39 months), the data suggest that doxycycline is
macroWlaricidal on its own.
Adverse events
One patient in the 4-week group presented with bloody
diarrhoea on day 3 of treatment. The treatment was stopped
and the patient recovered quickly after treatment with met-
ronidazole. Day 3 may have been too early for antibiotic-
associated colitis. Other side eVects were mild, did not last
longer than 3 days and did not occur more frequently after
administration of doxycycline. No serious adverse events
were observed. One patient from the 4-week doxycycline
group died 8 months after doxycycline treatment without
conWrming any diagnosis. Dying adult Wlariae in superWcial
tissues may perforate the tissue, as it has been observed
with suramin treatment of onchocerciasis or diethylcyar-
Table 6 MacroWlaricidal activity of doxycycline treatment: percentage of dead and living Wlariae. Results of immunohistology
a,b SigniWcant diVerence between the respective doxycycline and the placebo groups regarding the proportion of dead female worms at the respec-
tive time point compared to the placebo group: a P < 0.0001; b P = 0.005 (Fisher’s exact test)
c,d SigniWcant diVerence between the respective doxycycline and the placebo groups regarding the proportion of dead male worms at the respective
time point: c P =0 . 0 0 3 ;   d P = 0.013 (Fisher’s exact test). No signiWcant diVerences between the two doxycycline groups were observed at any time
point
e Arithmetic mean and standard error (SE)
f,g,h,i SigniWcant diVerences in the respective doxycycline compared to the placebo groups at the respective point of time: f P =0 . 0 0 9 ;   g P = 0.0004;
h P < 0.0001; i P = 0.0002 (Mann–Whitney-U test). No signiWcant diVerences between the two doxycycline groups were observed at any time point
Treatment group Time 
(months)
Number of 
patients/nodules
Number of 
female worms
Number of 
male worms
Number of living 
worms per nodule
All Dead females
(%)
All Dead males
(%)
Female Male
Mean
(SEe)
Mean
(SEe)
Placebo 6 13/14 35 6
(17%)
80
(0)
2.1
(0.5)
0.6
(0.2)
20 16/51 93 23
(25%)
27 2
(7%)
1.4
(0.2)
0.5
(0.1)
27 7/38 78 17
(22%)
26 1
(4%)
1.6
(0.2)
0.7(0.1)
Doxycycline (4 weeks) 20 7/36 55 28
(51%)a
28 7
(25%)
0.8f
(0.2)
0.6
(0.1)
27 7/23 39 19
(49%)b
16 7
(44%)c
0.6g
(0.2)
0.4
(0.1)
Doxycycline (6 weeks) 6 11/19 41 9
(22%)
18 0
(0) 
1.7
(0.3)
0.9
(0.3)
20 13/62 111 69
(62%)a
31 11
(35%)d
0.7h
(0.2)
0.3
(0.1)
27 5/27 38 23
(61%)a
17 3
(18%)
0.6i
(0.2)
0.5
(0.1)Med Microbiol Immunol (2008) 197:295–311 307
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bamazine (DEC) treatment of Brugia infections. If this hap-
pens, the patients always become aware of it. None of our
doxycycline-treated patients reported a perforation and all
scars observed in November 2006 were identical with the
sites of nodulectomies. Since doxycycline does not show a
fast microWlaricidal activity, no side eVects known to occur
with DEC or IVM were observed during the treatment or
reported later by the patients.
Discussion
Selection of villages and treatment with placebo
The three neighbouring villages selected for the study were
located in an area with ongoing transmission [21]. This
probably led to the acquisition of new worms during the
study, presenting a problem for the diagnosis of worm
vitality (see below). However, performing the study in an
area with strongly reduced or interrupted transmission
would have biased the results, as older worm populations
present more degenerated and dead worms [23]. This would
also present a bias for the diagnosis of any macroWlaricidal
activity. DiVering from our previous study [16–18] the
present study was placebo-controlled and randomised. The
recruitment of placebo patients in a randomized way from
the same villages is nowadays necessary, since comparison
to historical data sets may be biased due to IVM mass treat-
ment or vector control, resulting in a diVerent age pattern of
the worms.
Remaining living worms and acquisition of new worms 
after doxycycline
At 20 and 27 months after doxycycline treatment, the tables
show a few living worms with many Wolbachia (Table 2),
female worms with normal embryogenesis (Table 3), and
approximately 40 and 50% surviving females in the 6 and
4-week groups, respectively (Table 4). To explain these
Wndings we consider three hypotheses, which probably are
all true for some of the Wlariae:
(1) Some worms survive for longer periods without the
endobacteria but they do not resume mf production for
several years or for the rest of their lives. Such survival of
worms after treatment is well known for O. volvulus after
suramin [25]. Cure rates at this extent are also known from
other tissue-dwelling helminths and are accepted provided
a reduction of the worm load is achieved. For example,
Schistosoma cure rates of 60–95% are accepted by WHO
[41]. Also for loiasis and lymphatic Wlariasis for some
patients several courses of DEC are needed for a cure. (2)
Not all endobacteria have been eliminated from the Wlariae
and these may multiply over a period of time, as it is known
from Rickettsia. We suppose that survival of a few bacteria
in degenerated oocytes or embryos might happen when
suboptimal doses of the antibiotic are used. (3) Based on
our observations we are convinced that the worms with
many bacteria (Fig. 3) and with either undisturbed oogene-
sis or embryogenesis were newly acquired after the doxy-
cycline administration. Given that a female worm’s average
life span is 10 years [2] and the worm load in adult humans
in areas with ongoing transmission such as the study area,
is rather stable, one has to consider a yearly turnover of
approximately 10% of the total adult worm load. Therefore,
during an observation period of up to 27 months, a rate of
20% of newly acquired young worms would have to be
expected. These young female worms can be diVerentiated
from older worms by their morphology [18, 23,  42–44].
The young female worms are characterized by: a smaller
diameter, no thickening of the cuticle, prominent lateral
cords and somatic muscles, lack of inclusion bodies or
other signs of degeneration in hypodermis, muscles, and
epithelia. Most are still nulliparous. Little or no intense
brown or blue staining is seen in the gut and none in other
organs because of less iron deposition [45]. In accordance
with these results, the APR-positive lysosomes are not
found in immature worms, and they are rare in the gut and
more so in the other tissues of young worms compared to
the older ones [27].
In our histological analyses we observed the presence of
such worms, especially when we examined the slides
stained by anti-APR-serum (Fig. 3) or by Gomori’s method
for iron. Applying these criteria and subtracting these
newly acquired living worms from the total, the proportion
of dead female worms would be higher, around 70% in the
6-week doxycycline group at both months 20 and 27, com-
pared to only 30% in the placebo group. In particular, the
alternating logistic regression analysis for the rates of living
female worms per nodule at 20 months is disproportion-
ately aVected by the newly acquired worms, as most of the
nodules in the doxycycline group with living worms are
comprised only of new worms. In addition, some dead
worms may have been absorbed. Assuming that 70% or
more worms have died, up to 30% of the female and a
higher percentage of male worms would have survived
without endobacteria, albeit sterile and degenerated. This
represents a considerable reduction of the adult worm load
and together with the complete sterilisation (except for new
worms) apparently meets the criteria of cure applied for
other helminths [41].
Interdependency issues
The primary outcome of this study was the assessment of
sustained eVects of doxycycline treatment on worm fertility
and worm survival. This outcome was evaluated also by308 Med Microbiol Immunol (2008) 197:295–311
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taking into consideration possible interference, since
worms aggregate in nodules, arguably in order to enhance
their chances to mate and produce oVspring, and to survive.
Therefore, we used alternating logistic regression to com-
pare, between the treatment arms, the rate of nodules with
normal embryogenesis, the rate of nodules with mf, and the
rate of nodules with living female worms. Interestingly, the
results for alternating logistic regression showed almost
identical proportions of living and dead female worms
compared to the analysis of individual worms, as shown in
Table 4. However, analysed by alternating logistic regres-
sion, the data on this are now comparable to the mode of
analysis by Duke and colleagues [28].
MacroWlaricidal activity of doxycycline
It may be asked whether the macroWlaricidal eVect seen in
this study in the patients who received doxycycline has
only been achieved in conjunction with the administration
of IVM. A preliminary answer to this may be given from
the analysis of the small number of nodules from patients
who had received only doxycycline, because they had
missed the IVM administration in our study. The Wndings
from these nodules allowed the assumption that doxycy-
cline is macroWlaricidal on its own. This was conWrmed by
the data of another study where the patients did not receive
IVM (Hoerauf et al., in preparation).
Safety of doxycycline treatment
Doxycycline for bacterial infections has been used by mil-
lions of people against bacterial infections, including prob-
ably tens of thousands with Wlarial co-infections. It is a safe
drug as long as the contraindications are observed. We have
used it previously to treat bacterial infections of onchocer-
ciasis patients. Considering the large number of treated
people, it was certainly not an objective of this study to
assess the safety of doxycycline in general. However, we
Fig. 3 Living O. volvulus worms acquired before and after doxycy-
cline treatment without and with Wolbachia endobacteria. a At left an
old female worm without endosymbionts and at right a young newly
acquired female and a male worm with red labelled Wolbachia (open
arrowhead). Onchocercoma excised at 27 months. b As in (a), at left
an old female and at right new young worms at 20 months (open
arrowhead). c Another section of the old female shown in (b)—but
from another place of the same slide—without Wolbachia and embry-
os and with a dark, pigmented gut (closed arrowhead). d Detail of (b)
showing both the young female and male worms with endobacteria la-
belled in red (open arrowheads). The gut is less pigmented (closed
arrowhead) and the uterus contains coiled microWlariae (arrow). Sec-
tions stained with antiserum against Wolbachia surface protein (Di-
Wsp). Scale bar = 100 mMed Microbiol Immunol (2008) 197:295–311 309
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did consider which side eVects might be expected regarding
anti-Wlarial activity of doxycycline. Since doxycycline has
no or at least no fast microWlaricidal activity, adverse side
eVects known from DEC or IVM were not to be expected.
Therefore we assumed that an ophthalmologic examination
was not needed for this study. Regarding the macroWlari-
cidal activity, subcutaneous abscesses and rarely perfora-
tion of the subcutaneous tissue and the skin by moribund or
dead  Wlariae may occur, as with suramin treatment of
onchocerciasis or DEC with Brugia infections. This did not
occur during our study.
Conclusions
The present study showed that doxycycline not only inter-
rupts embryogenesis in the long-term, but also has a macro-
Wlaricidal activity in human onchocerciasis. The treatment
has a low toxicity except for pregnant and lactating women
and children below the age of 9 years. The sustained
absence of embryogenesis, of skin mf and the macroWlari-
cidal activity seemed to be better after 6 weeks as compared
to 4 weeks of doxycycline administration (P = 0.07 for the
combined 20 and 27 months groups, Chi-square test); simu-
lating the same proportions of dead and living worms with
higher numbers would result in a statistically signiWcant
diVerence. Therefore, doxycycline should rather be used for
6 weeks, if possible. Larger studies may show that the
4-week regimen is equivalent for certain indications, such as
long-term sterilisation.
The new chemotherapeutic principle is beneWcial to the
treatment of individual patients, who have left a transmis-
sion area and thus can achieve a strong reduction of the
adult worm load and a clearance of mf. The new regimen
may also be considered in areas where there has been evi-
dence for a sub-optimal performance of IVM as in the Asu-
bende focus in Ghana [12–14]. Worm populations that
might have acquired some degree of resistance may thus be
eliminated with an existing drug to prevent resistance from
further spreading. Doxycycline without IVM may also be
considered for treatment in areas with co-endemicity of
onchocerciasis and loiasis. In addition, the elimination of
onchocerciasis in the Americas has reached “end-game”
scenarios where transmission has apparently been inter-
rupted and there are only a limited number of people
infected with onchocerciasis in some foci. Administration
of doxycycline to these people has been suggested ([46],
and F. Richards, Atlanta, personal communication) on the
basis of its long-term embryotoxicity. The new data on the
macroWlaricidal eVect further underscores this argumenta-
tion. In these foci children are usually no longer infected
and pregnant and lactating women can be treated later. The
anti-wolbachial chemotherapeutic principle may also be
exploited for the search of new macroWlaricidal drugs,
which can be focussed on Wolbachia-depleting antibiotics.
Indications have been dealt with in more detail in [47].
In summary, anti-wolbachial chemotherapy of human
onchocerciasis with doxycycline can be orally applied for
special indications to sterilise the female Wlariae and to
reduce the adult worm load. It cannot replace IVM for mass
treatment in areas with ongoing transmission.
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